BioAge Labs (NASDAQ:BIOA) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of BioAge Labs (NASDAQ:BIOA) from a sell rating to a hold rating in a report issued on Saturday morning.

BIOA has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Thursday, October 30th. Citigroup boosted their price target on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $15.00.

BioAge Labs Price Performance

NASDAQ:BIOA opened at $11.61 on Friday. BioAge Labs has a twelve month low of $2.88 and a twelve month high of $20.37. The firm has a market cap of $416.22 million, a price-to-earnings ratio of -7.64 and a beta of 1.74. The business’s 50 day moving average is $7.34.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.11. The company had revenue of $2.05 million during the quarter.

Insiders Place Their Bets

In other BioAge Labs news, insider Paul D. Rubin sold 68,897 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $10.19, for a total transaction of $702,060.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 20.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioAge Labs

Institutional investors and hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio acquired a new stake in BioAge Labs during the 2nd quarter worth approximately $57,000. Geode Capital Management LLC increased its position in BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after buying an additional 171,426 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of BioAge Labs during the second quarter worth $27,000. Intech Investment Management LLC bought a new stake in shares of BioAge Labs in the second quarter valued at about $60,000. Finally, Jefferies Financial Group Inc. acquired a new position in shares of BioAge Labs in the second quarter valued at about $206,000.

BioAge Labs Company Profile

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.